Publication | Open Access

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

VaccinationVaccine SafetyVaccine DevelopmentImmunologyVirologyNon-randomised Phase 1/2Polyvalent VaccineMedicineVaccine ResearchCovid-19